198 related articles for article (PubMed ID: 35939302)
1. Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes.
Lin E; Garmo H; Van Hemelrijck M; Zethelius B; Stattin P; Hagström E; Adolfsson J; Crawley D
JAMA Netw Open; 2022 Aug; 5(8):e2225600. PubMed ID: 35939302
[TBL] [Abstract][Full Text] [Related]
2. Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study.
Lin E; Garmo H; Van Hemelrijck M; Adolfsson J; Stattin P; Zethelius B; Crawley D
BMC Cancer; 2021 Nov; 21(1):1259. PubMed ID: 34809595
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.
Thomsen FB; Sandin F; Garmo H; Lissbrant IF; Ahlgren G; Van Hemelrijck M; Adolfsson J; Robinson D; Stattin P
Eur Urol; 2017 Dec; 72(6):920-928. PubMed ID: 28711383
[TBL] [Abstract][Full Text] [Related]
4. Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden.
Lin E; Garmo H; Hagström E; Van Hemelrijck M; Adolfsson J; Stattin P; Zethelius B; Crawley D
Br J Cancer; 2023 Mar; 128(5):814-824. PubMed ID: 36522475
[TBL] [Abstract][Full Text] [Related]
5. Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden.
George G; Vikman H; Gedeborg R; Lissbrant IF; Garmo H; Styrke J; Van Hemelrijck M; Stattin P
Acta Oncol; 2021 Apr; 60(4):459-465. PubMed ID: 33606571
[TBL] [Abstract][Full Text] [Related]
6. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
[TBL] [Abstract][Full Text] [Related]
7. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
Thomsen FB; Bosco C; Garmo H; Adolfsson J; Hammar N; Stattin P; Van Hemelrijck M
Acta Oncol; 2019 Jan; 58(1):110-118. PubMed ID: 30375907
[TBL] [Abstract][Full Text] [Related]
8. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases.
George G; Garmo H; Scailteux LM; Balusson F; De Coster G; De Schutter H; Kuiper JG; Oger E; Verbeeck J; Van Hemelrijck M
Int J Cancer; 2021 May; 148(9):2203-2211. PubMed ID: 33186481
[TBL] [Abstract][Full Text] [Related]
9. Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.
Bosco C; Wong C; Garmo H; Crawley D; Holmberg L; Hammar N; Adolfsson J; Stattin P; Van Hemelrijck M
BJU Int; 2018 Feb; 121(2):260-267. PubMed ID: 28940667
[TBL] [Abstract][Full Text] [Related]
10. Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study.
Crawley D; Garmo H; Rudman S; Stattin P; Zethelius B; Armes J; Holmberg L; Adolfsson J; Van Hemelrijck M
BMJ Open; 2018 Mar; 8(3):e020787. PubMed ID: 29549214
[TBL] [Abstract][Full Text] [Related]
11. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
[TBL] [Abstract][Full Text] [Related]
12. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
13. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
Chen DY; Su PJ; See LC; Liu JR; Chuang CK; Pang ST; Tseng CN; Chen SW; Hsieh IC; Chu PH; Lin YC; Hsu CL; Chang JW; Lin MS; Pang JS; Hsieh MJ; Huang WK
Prostate; 2021 Sep; 81(12):902-912. PubMed ID: 34196430
[TBL] [Abstract][Full Text] [Related]
15. Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists.
Bonde TM; Garmo H; Stattin P; Nilsson P; Gunnlaugsson A; Swanberg D; Robinson D
Acta Oncol; 2023 Dec; 62(12):1815-1821. PubMed ID: 37850633
[TBL] [Abstract][Full Text] [Related]
16. Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases.
George G; Scailteux LM; Garmo H; Balusson F; Cardwell C; Coster G; Schutter H; Kuiper JG; McMenamin Ú; Verbeeck J; Van Hemelrijck M
Fundam Clin Pharmacol; 2019 Aug; 33(4):479-499. PubMed ID: 30776136
[TBL] [Abstract][Full Text] [Related]
17. Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden.
George G; Garmo H; Rudman S; Holmberg L; Robinson D; Stattin P; Adolfsson J; Van Hemelrijck M
Scand J Urol; 2020 Feb; 54(1):20-26. PubMed ID: 31842658
[No Abstract] [Full Text] [Related]
18. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.
Bonde TM; Westerberg M; Aly M; Eklund M; Adolfsson J; Bill-Axelson A; Garmo H; Stattin P; Robinson D
Scand J Urol; 2022 Jun; 56(3):169-175. PubMed ID: 35548951
[No Abstract] [Full Text] [Related]
19. Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan.
Shao YJ; Hong JH; Chen CK; Huang CY
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):722-729. PubMed ID: 35662291
[TBL] [Abstract][Full Text] [Related]
20. Long-term Cardiovascular Risks of Gonadotropin-releasing Hormone Agonists and Antagonists: A Population-based Cohort Study.
Chan JSK; Lee YHA; Hui JMH; Liu K; Dee EC; Ng K; Tang P; Tse G; Ng CF
Clin Oncol (R Coll Radiol); 2023 Jun; 35(6):e376-e383. PubMed ID: 37031076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
